Posted by Michael Wonder on 02 Apr 2020
Proposal to fund modified release pancreatic enzyme granules (Creon Micro)
2 April 2020 - PHARMAC is seeking feedback on a proposal to fund a new modified-release granule formulation of pancreatic enzymes (Creon Micro), which is used for the treatment of pancreatic enzyme insufficiency, from 1 June 2020 through a provisional agreement with Mylan.
From 1 June 2020, people who have pancreatic insufficiency would have funded access to a new modified-release granule formulation of pancreatic enzymes, Creon Micro. This would mean that people who require small doses would have access to a funded product.
Currently, PHARMAC funds capsule formulations of pancreatic enzymes. However, we are aware that some patients, in particular paediatric patients with cystic fibrosis, require smaller doses than contained in the funded capsules. We understand that carers currently empty capsules into a measure of food puree and then divide the puree into a half or quarter portion depending on the dose required. The remainder is then discarded.
